Canadian Foundation for Translational Immunology
Public foundation · Vancouver, British Columbia · BN 747425528RR0001 · Foundations
Source: T3010 return, FPE 2024-12-31. Split of total expenditures ($75,100) as filed with the CRA.
Canadian Foundation for Translational Immunology is a public foundation based in Vancouver, British Columbia, classified by the CRA under foundations. In its fiscal year ending December 31, 2024, it reported $2,158 in revenue and $75K in expenditures. Spending exceeded revenue that year — the gap came out of reserves.
Compared with 3,025 grantmaking charities of similar size, its share of spending on mission — charitable programs plus grants to other charities — ranked above 78% of peers.
Revenue has declined over its filings on record here, from $6,000 in 2020 to $2,158 in 2024. Its filed list of directors and trustees shows 3 names.
In its own words
Develop therapeutics to target androgen-deprivation-therapy induce dormancy in order to prevent or delay prostate-cancer progression to incurable castration-resistant prostate cancer.
Ongoing-program description from its T3010 filing, verbatim.
The ledger, 2020–2024
| Year | Revenue | Spending | Programs | Fundraising | Gifts out | Net assets |
|---|---|---|---|---|---|---|
| 2024 | $2,158 | $75K | $75K | — | — | $6,327 |
| 2023 | $3,538 | $100 | — | — | — | $79K |
| 2022 | $3,581 | $2,650 | — | — | — | $76K |
| 2021 | $6,000 | — | — | — | — | $75K |
| 2020 | $6,000 | $77 | — | — | — | $69K |
Revenue printed in red where the year ran a deficit. Fiscal years by period end.
Directors & trustees (2024)
Gordon Killam (director); Sasha Smiljanic (director); Howard Simons (director).
As listed on its 2024 return.
Check the source
Every figure on this page is from Canadian Foundation for Translational Immunology’s own T3010 filings, published by the Canada Revenue Agency. Verify against the CRA’s charities listing (search BN 747425528RR0001), or read how we compute the receipt.